

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Horizon Health Limited

諾輝健康

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 6606)

**(1) ADDITIONAL RESUMPTION GUIDANCE;
(2) CHANGE OF ADDRESS OF PRINCIPAL PLACE OF
BUSINESS IN HONG KONG;
AND
(3) CONTINUED SUSPENSION OF TRADING**

This announcement is made by New Horizon Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Reference is made to (i) the announcement of the Company dated March 28, 2024 in relation to the suspension of trading in the shares of the Company on the Stock Exchange with effect from 9:00 a.m. on March 28, 2024; (ii) the announcement of the Company dated March 28, 2024 in relation to, among others, the delay in publication of the 2023 Annual Results; (iii) the announcement of the Company dated April 8, 2024 in relation to, among others, the establishment of the Independent Special Committee; (iv) the announcement of the Company dated May 28, 2024 on the Resumption Guidance from the Stock Exchange (“**Initial Resumption Guidance**”); (v) the announcement of the Company dated June 28, 2024 in relation to the first quarterly update on resumption progress; (vi) the announcement of the Company dated September 9, 2024 in relation to the resignation of the Company’s auditor; (vii) the announcement of the Company dated September 27, 2024 in relation to the appointment of

a new auditor of the Company; (viii) the announcement of the Company dated September 27, 2024 in relation to, among others, the second quarterly update on resumption progress; (ix) the announcement of the Company dated December 27, 2024 in relation to the third quarterly update on resumption progress; and (x) the announcement of the Company dated January 6, 2025 in relation to the resignation of an Independent Non-executive Director and non-compliance with Rule 3.21 of the Listing Rules (collectively, the “**Announcements**”).

Unless otherwise stated, capitalized terms used in this announcement shall bear the same meanings as those defined in the Announcements.

ADDITIONAL RESUMPTION GUIDANCE

As disclosed in the announcement of the Company dated January 6, 2025, following the resignation of Dr. Li, an independent non-executive Director, the Audit Committee is currently comprising two members, being one non-executive Director and one independent non-executive Director, which resulted in non-compliance by the Company with the requirements of the Audit Committee having a minimum of three members and comprising a majority of independent non-executive Directors as required under Rule 3.21 of the Listing Rules.

Due to the above circumstance, the Company received a letter from the Stock Exchange on January 6, 2025, pursuant to which, the Stock Exchange imposes the following additional resumption guidance (the “**Additional Resumption Guidance**”, together with the Initial Resumption Guidance, the “**Resumption Guidance**”) for the resumption of trading in the shares of the Company:

- (i) Re-comply with Rule 3.21 of the Listing Rules.

The Stock Exchange further indicated that it may modify the Resumption Guidance and/or give further guidance as and when appropriate.

CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of the Company hereby announces that with effect from January 10, 2025, the address of the principal place of business in Hong Kong of the Company will be changed to Room 1920, 19/F, Lee Garden One, 33 Hysan Avenue, Causeway Bay, Hong Kong.

CONTINUED SUSPENSION OF TRADING

Trading in the Company's shares on the Stock Exchange has been suspended since March 28, 2024 and will remain suspended until further notice.

Shareholders and potential investors should exercise caution when dealing in the securities of the Company.

By order of the Board
New Horizon Health Limited
Mr. Naxin Yao
Chairman

Hong Kong, January 9, 2025

As at the date of this announcement, the Board comprises Mr. Naxin YAO as Chairman and non-executive Director, Dr. Yiyong CHEN and Mr. Yeqing ZHU as executive Directors, and Mr. Danke YU, Mr. LAU Ngai Kee Ricky, Ms. NG Weng Sin and Ms. Jiangnan KONG as independent non-executive Directors.